Market Overview

Novartis: Q3 Earnings Insights



Shares of Novartis (NYSE:NVS) decreased 1.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 7.80% year over year to $1.52, which beat the estimate of $1.45.

Revenue of $12,259,000,000 rose by 0.71% year over year, which missed the estimate of $12,530,000,000.


Novartis hasn't issued any earnings guidance for the time being.

Novartis hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Oct 27, 2020

Time: 09:00 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $99.84

52-week low: $69.18

Price action over last quarter: down 4.24%

Company Profile

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.


Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: Earnings News